Söndag 19 Oktober | 19:45:42 Europe / Stockholm

Prenumeration

2025-10-19 16:43:00

Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc. Based on the currently available information, we expect a new PDUFA date in either Q2 or Q3 next year and have adjusted our fair value range accordingly.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/